Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1228 ARTÍCULOS , VIENDO DEL 1006 AL 1020

The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis

Kobayashi H, Ohnishi T, Nakagawa R, Yoshizawa K.

Int J Geriatr Psychiatry. 2016 Aug;31(8):892-904. doi: 10.1002/gps.4405. Epub 2015 Dec 17.

Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project

Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S; European Prevention of Alzheimer's Dementia (EPAD) Consortium.

Lancet Psychiatry. 2016 Feb;3(2):179-86. doi: 10.1016/S2215-0366(15)00454-X. Epub 2015 Dec 10.

Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?

St-Amour I, Cicchetti F, Calon F.

Acta Neuropathol. 2016 Apr;131(4):481-504. doi: 10.1007/s00401-015-1518-9. Epub 2015 Dec 21.

Early psychiatrics symptoms in familial Alzheimer's disease with presenilin 1 mutation (I83T)

Fray S, Ali NB, Rassas AA, Kechaou M, Oudiaa N, Cherif A, Echebbi S, Messaoud T, Belal S.

J Neural Transm (Vienna). 2016 Apr;123(4):451-3. doi: 10.1007/s00702-015-1498-x. Epub 2015 Dec 22.

Getting to NO Alzheimer's Disease: Neuroprotection versus Neurotoxicity Mediated by Nitric Oxide

Balez R, Ooi L.

Oxid Med Cell Longev. 2016;2016:3806157. doi: 10.1155/2016/3806157. Epub 2015 Nov 30.

Accelerating stem cell trials for Alzheimer's disease

Hunsberger JG, Rao M, Kurtzberg J, Bulte JWM, Atala A, LaFerla FM, Greely HT, Sawa A, Gandy S, Schneider LS, Doraiswamy PM.

Lancet Neurol. 2016 Feb;15(2):219-230. doi: 10.1016/S1474-4422(15)00332-4. Epub 2015 Dec 17.

Examining the reliability of ADAS-Cog change scores

Grochowalski JH, Liu Y, Siedlecki KL.

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2016 Sep;23(5):513-29. doi: 10.1080/13825585.2015.1127320. Epub 2015 Dec 28.

Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis

Kandimalla R, Reddy PH.

Biochim Biophys Acta. 2016 Apr;1862(4):814-828. doi: 10.1016/j.bbadis.2015.12.018. Epub 2015 Dec 17.

Propagation of Aß pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies

Eisele YS, Duyckaerts C.

Acta Neuropathol. 2016 Jan;131(1):5-25. doi: 10.1007/s00401-015-1516-y. Epub 2015 Dec 29.

Mechanical stress models of Alzheimer's disease pathology

Levy Nogueira M, Epelbaum S, Steyaert JM, Dubois B, Schwartz L.

Alzheimers Dement. 2016 Mar;12(3):324-33. doi: 10.1016/j.jalz.2015.10.005. Epub 2015 Dec 21.

Amyloid-β Receptors: The Good, the Bad, and the Prion Protein

Jarosz-Griffiths HH, Noble E, Rushworth JV, Hooper NM.

J Biol Chem. 2016 Feb 12;291(7):3174-83. doi: 10.1074/jbc.R115.702704. Epub 2015 Dec 30.

Amyloid β-interacting partners in Alzheimer's disease: From accomplices to possible therapeutic targets

Han SH, Park JC, Mook-Jung I.

Prog Neurobiol. 2016 Feb;137:17-38. doi: 10.1016/j.pneurobio.2015.12.004. Epub 2015 Dec 23.

New insights on the role of microglia in synaptic pruning in health and disease

Hong S, Dissing-Olesen L, Stevens B.

Curr Opin Neurobiol. 2016 Feb;36:128-34. doi: 10.1016/j.conb.2015.12.004. Epub 2015 Dec 30.

Depression as a risk factor for Alzheimer's disease: Genes, steroids, cytokines and neurogenesis - What do we need to know?

Herbert J, Lucassen PJ.

Front Neuroendocrinol. 2016 Apr;41:153-71. doi: 10.1016/j.yfrne.2015.12.001. Epub 2015 Dec 30.

Neuroinflammation: A common denominator for stroke, multiple sclerosis and Alzheimer's disease

Vries HE, Schwaninger M.

Biochim Biophys Acta. 2016 Mar;1862(3):297-8. doi: 10.1016/j.bbadis.2015.12.024. Epub 2015 Dec 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias